BioCentury on BioBusiness,
How adding Amylin gives partners BMS, AstraZeneca leverage in diabetes
Related tables, figures and sidebars
Triple play in diabetes
Monday, July 9, 2012
The addition of Amylin
Pharmaceuticals Inc.'s glucagon-like peptide 1 franchise will give
Squibb Co. and AstraZeneca
plc three modern mechanisms in their commercial diabetes portfolio and
five in the pipeline - more than any other players in the diabetes space.
Amylin's two GLP-1 products - once-weekly Bydureon exenatide
and twice-daily Byetta exenatide - together are the second-ranked GLP-1s by
sales behind Novo
Nordisk A/S's Victoza liraglutide. But BMS and AZ believe
they can boost sales of Bydureon by leveraging their much larger sales
organizations, which have greater reach into primary care and emerging markets
than Amylin would have been able to accomplish on its own.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]